Sunflower Pharmaceutical Group (002737.SZ) plans to acquire 100% equity of Dongxu Pharmaceutical.

Sunflower Pharmaceutical Group (002737.SZ) announced that the company has decided to use its own funds of RMB 780,000 to acquire a total of 100% equity (corresponding to registered capital of RMB 5 million) in Heilongjiang Dongxu Pharmaceutical Co., Ltd. ("Dongxu Pharmaceutical") held by natural persons Yang Dongxu and Yang Huaizhou. The acquisition aims to promote separate-line operations and independent management across various business segments of the marketing system, mobilize organizational effectiveness, and improve operational efficiency. After the transaction is completed, Dongxu Pharmaceutical will become a wholly-owned subsidiary of the company and will be included in the company's consolidated financial statements.